What's Next for Personalized Medicine? | Sapient Bio CEO Dr. Jonathan Usuka

Dr. Jonathan Usuka, CEO of Sapient Bio, is building high-dimensional proteomics platforms to help pharma understand disease at the molecular level and develop more targeted therapies.With a career spanning early computational genomics during the Human Genome Project, to R&D roles at Roche and Celgene, and later pharmaceutical analytics at McKinsey, he has consistently worked at the intersection of biology and data. In this episode, we explore the shift from organ-based definitions of disease to biomarker-driven subtypes and ultimately toward truly personalized medicine. We discuss why proteins and metabolites—not just DNA—are key to understanding what’s actually happening inside patients in real time. We also dive into how AI is unlocking massive amounts of clinical data and why the biggest bottlenecks today lie in clinical trials, patient identification, and making sense of increasingly complex biological systems.